Tebentafusp before surgery for uveal melanoma in the liver
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a drug called tebentafusp before surgery for uveal melanoma that has spread to the liver. The goal is to see if giving the drug first can shrink the tumors and make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have uveal melanoma that has spread to the liver, and the liver tumors should be possible to remove with surgery.
- You need to have a specific genetic marker called HLA-A*02:01.
- You cannot have had any prior treatments for metastatic disease, including chemotherapy, immunotherapy, or local treatments to the liver.
- You must be in generally good health (able to do daily activities) and have adequate organ function (kidney, liver, blood counts).
- The cancer must only be in the liver, not in other parts of the body.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Tebentafusp for a type of eye melanoma (uveal melanoma) that is too large to be removed without taking out the whole eye. The goal is to see if the drug can shrink the tumor before deciding on surgery.
This trial tests a new drug called tebentafusp for people with uveal melanoma that has spread to other parts of the body and who have not yet received any treatment for the metastatic disease. It requires a specific genetic marker (HLA-A*0201) and focuses on whether the drug can shrink or slow the growth of tumors.
This trial tests a combination of two drugs (tebentafusp and a liver-directed treatment called LDT) for people with uveal melanoma that has spread to the liver. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a new drug called tebentafusp given after standard treatment (surgery or radiation) for high-risk uveal melanoma that hasn't spread. The goal is to see if it helps prevent the cancer from coming back.
This trial tests whether combining a drug called tebentafusp with a procedure called radioembolization can help control uveal melanoma that has spread mainly to the liver. Radioembolization delivers tiny radioactive beads to the liver, and tebentafusp helps your immune system attack the cancer.
This trial tests a two-part treatment for uveal melanoma that has spread to the liver. First, you get a liver-directed chemotherapy (melphalan) through a special procedure called PHP, then you receive an immunotherapy drug (tebentafusp) that helps your immune system attack the cancer.
Hear when a new Mestastatic Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.